Want to see HK:2235 full AI Analyst Report?
MicroTech Medical (Hangzhou) Co., Ltd. Class H (2235) AI Stock Analysis
MicroTech Medical (Hangzhou) Co., Ltd. Class H
(HKEX:2235)
The score is driven primarily by strong financial fundamentals on growth and balance-sheet conservatism, including a return to positive net income. These positives are tempered by still-developing cash flow (negative free cash flow) and weak technical momentum, while the high P/E valuation reduces upside-adjusted attractiveness.
MicroTech Medical (Hangzhou) Co., Ltd. Class H (2235) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 2.82B
- Dividend Yield
- ―
- Average Volume (3M)
- 68.78K
- Price to Earnings (P/E)
- 27.6
- Beta (1Y)
- 0.20
- Revenue Growth
- 94.80%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 702
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
MicroTech Medical (Hangzhou) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
MicroTech Medical (Hangzhou) Co., Ltd. focuses on the innovation, production, and market distribution of essential medical devices and consumables for diabetes management. Its operations extend across the People's Republic of China and into global ma...
How the Company Makes Money
The company makes money primarily by selling diabetes management medical devices and the recurring consumables required to use them. Key revenue streams typically include: (1) sales of insulin pump systems (the durable device component), which may be...
MicroTech Medical (Hangzhou) Co., Ltd. Class H Financial Statement Overview
Summary
Strong and accelerating revenue growth (+101.1% in 2025) and stable ~53% gross margin are major positives. The balance sheet is a clear strength with very low leverage (debt-to-equity ~0.05). Offsetting this, operating profitability is not yet fully proven (EBIT/EBITDA still slightly negative) and cash flow quality remains mixed with negative free cash flow in 2025 (~-6.1M).
Income Statement
66PositiveBalance Sheet
84Very PositiveCash Flow
52Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 828.99M | 660.79M | 345.62M | 248.35M | 173.54M | 151.40M |
| Gross Profit | 469.39M | 357.42M | 182.85M | 123.22M | 79.66M | 70.88M |
| EBITDA | 109.72M | 31.40M | -119.65M | -184.12M | -109.86M | -39.80M |
| Net Income | 82.72M | 40.15M | -63.12M | -125.02M | -35.04M | -48.18M |
Balance Sheet | ||||||
| Total Assets | 2.34B | 2.31B | 2.15B | 2.16B | 2.29B | 2.33B |
| Cash, Cash Equivalents and Short-Term Investments | 1.54B | 1.55B | 1.71B | 1.89B | 2.05B | 2.15B |
| Total Debt | 110.20M | 91.37M | 4.20M | 5.06M | 717.00K | 255.00K |
| Total Liabilities | 293.53M | 287.07M | 171.72M | 97.70M | 82.06M | 82.48M |
| Stockholders Equity | 2.04B | 2.02B | 1.97B | 2.06B | 2.21B | 2.25B |
Cash Flow | ||||||
| Free Cash Flow | 29.99M | -6.11M | -203.88M | -181.69M | -137.45M | -62.94M |
| Operating Cash Flow | 85.30M | 31.80M | -120.65M | -153.00M | -107.67M | -44.22M |
| Investing Cash Flow | -36.27M | -351.63M | 121.16M | -540.70M | -965.58M | 97.69M |
| Financing Cash Flow | 21.94M | 55.22M | -33.15M | -23.46M | -20.57M | 1.57B |
MicroTech Medical (Hangzhou) Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2235, the sentiment is Negative. The current price of 6.70 is below the 20-day moving average (MA) of 6.84, below the 50-day MA of 6.92, and below the 200-day MA of 7.28, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 39.13 is Neutral, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2235.
MicroTech Medical (Hangzhou) Co., Ltd. Class H Peers Comparison
Overall Rating
HK:161267Neutral- HK:223558Neutral
HK:130256Neutral
HK:999648Neutral
HK:216043Neutral
HK:085341Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1612 | 67Neutral | HKD 468.67M | 4.77 | 13.95% | 6.48% | 10.95% | 9.26% |
| HK:2235 | 58Neutral | HKD 2.82B | 27.65 | 4.08% | ― | 94.80% | ― |
| HK:1302 | 56Neutral | HKD 6.35B | 98.22 | 1.71% | ― | 0.75% | -20.22% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:9996 | 48Neutral | HKD 2.55B | -15.11 | -7.65% | ― | 21.23% | 36.89% |
| HK:2160 | 43Neutral | HKD 1.63B | -0.86 | -6.69% | ― | ― | ― |
| HK:0853 | 41Neutral | HKD 11.65B | 31.23 | 6.07% | ― | -3.62% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2235 | MicroTech Medical (Hangzhou) Co., Ltd. Class H | 6.70 | -0.20 | -2.90% | |
| HK:0853 | MicroPort Scientific Corp | 6.08 | -5.92 | -49.33% | |
| HK:9996 | Peijia Medical Ltd. | 3.77 | -2.22 | -37.06% | |
| HK:1302 | LifeTech Scientific Corporation | 1.47 | -0.58 | -28.29% | |
| HK:1612 | Vincent Medical Holdings Limited | 0.71 | -0.10 | -12.24% | |
| HK:2160 | MicroPort CardioFlow Medtech Corp. | 1.28 | -4.67 | -78.49% |
MicroTech Medical (Hangzhou) Co., Ltd. Class H Corporate Events
MicroTech Medical Sets August Board Meeting to Review 2026 Interim Results and Possible Dividend
MicroTech Medical (Hangzhou) Co., Ltd. has scheduled a board meeting for August 21, 2026 to review and approve its unaudited interim results for the six months ended June 30, 2026, and to authorize their publication. The board will also consider whet...
MicroTech Medical Signals Strong H1 2026 Turnaround on CGM Growth
MicroTech Medical has issued a positive profit alert for the first half of 2026, projecting revenue of at least RMB400 million, up more than 63% year on year, and a net profit of at least RMB36 million, marking a turnaround from a loss in the same pe...
MicroTech Medical Wins South Korean Approval for Glucose Monitoring System
MicroTech Medical announced that its LinX Continuous Glucose Monitoring System has received marketing approval in South Korea for use in adult patients. South Korea is highlighted as a key East Asian market, with high diabetes prevalence, strong reim...
MicroTech Medical Shareholders Unanimously Back 2025 Results and Dividend Plan at AGM
MicroTech Medical (Hangzhou) Co., Ltd. held its 2025 annual general meeting in Hangzhou on June 10, 2026, with shareholders representing about 60.67% of voting rights in attendance. The meeting complied with PRC company law and the firm’s artic...
MicroTech Medical Sets 2025 AGM to Approve Results and Expand Capital Mandates
MicroTech Medical (Hangzhou) Co., Ltd. has convened its 2025 annual general meeting for June 10, 2026, in Hangzhou to seek shareholder approval of its 2025 annual report, audited financial statements and key governance reports from the board and supe...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 07, 2026